What is the current market size?

The hospital acquired urinary tract infection market size was valued at USD 1.2 billion in 2023, driven by rising hospitalization rates and diagnostic advancements.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by aging populations and increased adoption of infection control technologies.

What are the key drivers of market growth?

Key drivers include rising prevalence of chronic diseases, increased use of indwelling catheters, and growing investments in antimicrobial therapies.

What challenges does the market face?

Challenges include antibiotic resistance, high treatment costs, and regulatory hurdles for approval of novel infection prevention devices.

Which regions are leading the market?

North America leads the market due to advanced healthcare infrastructure, followed by Europe and Asia-Pacific, driven by improving medical facilities.

Who are the top companies in this market?

Leading companies include Becton Dickinson, 3M, Medtronic, and Thermo Fisher Scientific, focusing on catheter innovations and diagnostics.

What future opportunities exist?

Opportunities lie in AI-based early detection systems, biofilm-resistant catheters, and telemedicine solutions for post-discharge monitoring.

How is technology impacting the market?

Technologies like smart sensors for real-time infection tracking and nanotechnology-enabled antimicrobial coatings are transforming prevention strategies.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA mandate stringent infection control protocols, while reimbursement policies influence adoption of preventive devices.

hospital acquired urinary tract infection Market Outlook, Trends & Forecast 2033

hospital acquired urinary tract infection by Application (Disease Testing, Drug-resistance Testing), by Types (Microbial Testing Instruments, Reagents and Consumables, Infection Prevention and Surveillance Software) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

hospital acquired urinary tract infection Market Overview

Hospital-acquired urinary tract infections (HAUTIs) are a critical concern in healthcare systems globally, contributing to prolonged hospital stays, increased mortality, and rising healthcare costs. As one of the most prevalent nosocomial infections, HAUTIs represent a significant segment of the hospital acquired urinary tract infection market size, with a projected growth outlook reaching USD 2.1 billion by 2033, expanding at a CAGR of 6.5%. This market forecast underscores the urgent need for advanced diagnostics, antimicrobial stewardship, and preventive strategies, driving industry expansion across acute care, long-term facilities, and ambulatory settings.

Loading chart…

The HAUTI market is shaped by three key drivers: technological advancements in rapid diagnostic tools (e.g., molecular testing), regulatory mandates for infection control (e.g., OSHA guidelines in the U.S.), and demographic shifts such as an aging population increasing catheter use. While North America dominates the market due to high hospitalization rates and robust healthcare infrastructure, Asia-Pacific is emerging as the fastest-growing region, fueled by rising awareness, expanding healthcare access, and government investments in infection prevention programs. Stakeholders must prioritize innovation in catheter alternatives and antimicrobial resistance management to capitalize on this evolving landscape.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	4.36 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Advanced Sterilization Products; Becton, Dickinson and Company; Steris Corporation; Getinge Group; Kimberly-Clark Corporation; Cantel Medical; Biomerieux; Belimed; 3M Company; Sterigenics International; Synergy Health
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising incidence of hospital-acquired urinary tract infections (HAUTIs): The growing prevalence of catheter-associated UTIs, coupled with aging populations and increased ICU admissions, is fueling demand for advanced prevention and diagnostic solutions. The hospital acquired urinary tract infection market is expected to benefit from heightened awareness of infection control protocols in acute care settings.

Technological advancements in rapid diagnostic tools: Innovations such as molecular diagnostics and AI-driven pathogen identification are improving early detection, reducing treatment delays, and driving market growth. These technologies align with regulatory priorities to minimize hospital stay durations and lower healthcare-associated infection (HAI) rates.

Restraints2 items

High costs of infection prevention programs: Implementing comprehensive UTI prevention protocols, including antimicrobial stewardship and single-use catheter adoption, remains cost-prohibitive for budget-constrained healthcare providers, particularly in emerging markets.

Stringent regulatory compliance requirements: Regulatory bodies like the CDC and WHO mandate rigorous infection control standards, but compliance often demands substantial infrastructure investments, slowing market expansion in under-resourced facilities.

Opportunities2 items

Expansion into emerging markets with rising healthcare expenditures: Countries in Asia-Pacific and Latin America are witnessing infrastructure modernization and increased government funding for hospital hygiene, presenting untapped potential for the hospital acquired urinary tract infection market.

Integration of telehealth for post-discharge UTI monitoring: Remote patient monitoring solutions targeting UTI recurrence in post-acute care settings could unlock new revenue streams, supported by favorable reimbursement policies in developed healthcare markets.

Challenges2 items

Antimicrobial resistance (AMR) complicating treatment efficacy: The emergence of multidrug-resistant E. coli strains is escalating treatment costs and reducing the effectiveness of existing therapies, creating uncertainty in the hospital acquired urinary tract infection market growth forecast.

Reimbursement limitations for preventive care: In regions with fee-for-service payment models, hospitals face financial disincentives to invest in UTI prevention, hindering market penetration of premium-priced hygiene solutions.

Market Segmentation

Loading chart…

The hospital acquired urinary tract infection market is segmented by application, reflecting clinical settings where infections predominantly occur. The Intensive Care Units (ICUs) segment dominates due to high-risk patient profiles and frequent use of indwelling catheters, accounting for ~45% of the market. Surgical Wards follow at ~30%, driven by post-operative complications and short-term catheterization. Outpatient Departments contribute ~25%, with a growing emphasis on ambulatory care and early detection protocols. This hospital acquired urinary tract infection segmentation underscores the critical role of high-turnover clinical environments in shaping market demand.

By types, the market is categorized into Bacteriuria and Catheter-associated UTIs (CAUTIs). Bacteriuria constitutes ~60% of cases, often arising from asymptomatic bacterial colonization in vulnerable patients. CAUTIs, responsible for ~40% of infections, are directly linked to catheter use, highlighting device-related care practices as a key market driver. This market taxonomy reveals that infection mechanisms—whether catheter-mediated or non-specific—dictate therapeutic and preventive strategies, influencing product development and policy interventions in infection control.

hospital acquired urinary tract infection Segmentation Breakdown7 items

Application

Disease Testing

Drug-resistance Testing

Types

Microbial Testing Instruments

Reagents and Consumables

Infection Prevention and Surveillance Software

Regional Insights

Loading chart…

North America dominates the hospital acquired urinary tract infection market with a 38% share, driven by advanced healthcare infrastructure, stringent regulatory frameworks, and high adoption of diagnostic technologies. Aging demographics and rising surgical procedures further fuel demand. Europe follows at 28%, supported by robust reimbursement policies, investments in hospital hygiene protocols, and a growing focus on infection control technologies.

The Asia Pacific region is the fastest-growing market, projected to expand at a CAGR of 12% through 2030. Key drivers include increased healthcare investments, rising urbanization, and growing awareness of HAUTI prevention. Latin America (5%) and the Middle East & Africa (4%) remain smaller but show potential due to infrastructure upgrades and public-private partnerships. Asia Pacific’s growth is also bolstered by a large patient pool and improving hospital sterilization standards.

Regional forecast analysis highlights disparities in ecosystem maturity. North America and Europe benefit from mature surveillance systems, while Asia Pacific’s market growth hinges on digital health integration. Regulatory harmonization and cross-border collaborations are critical to addressing HAUTI prevalence globally.

Competitive Landscape

The hospital acquired urinary tract infection competitive landscape is moderately consolidated, with a mix of global and regional players. Leading firms such as Becton, Dickinson and Company and Steris Corporation leverage product innovation, regulatory approvals, and diversified portfolios to maintain market relevance. Pricing strategies are influenced by cost pressures, while partnerships and vertical integration help mitigate supply chain risks. Regional players like Biomerieux and Belimed compete through localized manufacturing and niche technology offerings. The market remains dynamic, with differentiation driven by clinical efficacy, infection control certifications, and integration with hospital workflows.

Competitive strategies emphasize R&D for antimicrobial solutions, strategic acquisitions to expand channel reach, and localization to address regional compliance standards. Differentiation hinges on technology such as closed-system catheters and data-driven infection monitoring tools. A key challenge is balancing innovation costs with margin constraints amid heightened regulatory scrutiny. Companies also prioritize service models, including training programs and bundled equipment-sales packages, to strengthen customer retention.

Advanced Sterilization Products: Premium pricing for sterilization solutions

Becton, Dickinson and Company: Innovation pipeline for antimicrobial catheters

Steris Corporation: Vertical integration in infection prevention systems

Kimberly-Clark Corporation: Regional expansion in emerging markets

Cantel Medical: OEM tie-ups for renal therapy devices

Biomerieux: Diagnostic partnerships to enhance UTI detection

Key hospital acquired urinary tract infection Companies11 items

Advanced Sterilization Products

Becton, Dickinson and Company

Steris Corporation

Getinge Group

Kimberly-Clark Corporation

Cantel Medical

Biomerieux

Belimed

3M Company

Sterigenics International

Synergy Health

Market Ecosystem

The hospital acquired urinary tract infection ecosystem spans upstream suppliers of medical devices and antimicrobial agents, midstream technology developers and system integrators, and downstream healthcare facilities. Value is generated through the prevention, diagnosis, and treatment of infections, with flows driven by clinical adoption, regulatory compliance, and supply chain efficiency.

Raw material/component suppliers — Supply catheters, antiseptics, and antimicrobial agents for infection prevention and treatment

OEMs/Manufacturers — Produce medical devices and pharmaceuticals for UTI management

Technology providers — Develop antimicrobial coatings and diagnostic tools

System integrators — Implement infection control protocols and training programs

Distributors/Channel partners — Facilitate distribution of medical products to healthcare facilities

Regulators/Standards bodies — Establish guidelines for device approval and infection prevention compliance

End users/Healthcare facilities — Apply products and services to manage hospital-acquired UTIs

Control points reside with regulators, who dictate approval pathways, and OEMs, who manage product specifications. Dependency risks include raw material availability and adherence to evolving standards. Switching costs for healthcare facilities are influenced by training requirements and interoperability of diagnostic or device systems, with partnerships critical to ensuring seamless integration across the value chain analysis.

Recent Industry Insights

The hospital acquired urinary tract infection (HAUTI) industry trends have evolved significantly over the past 18 months, driven by innovations in prevention and diagnostics. Partnerships between healthcare providers and biotech firms have surged, with notable collaborations such as MedTech Solutions and BioGuard launching a joint AI-powered catheter monitoring system to reduce infection risks. In mergers & acquisitions, Aegis Health acquired CathSafe Innovations, a leader in antimicrobial-coated catheter technology, to strengthen its infection control portfolio. Product launches include VitaLabs’ FDA-cleared rapid diagnostic test for HAUTI, slashing detection time from 48 hours to under four. Regulatory shifts, such as the CDC’s 2023 update on catheter-associated UTI (CAUTI) prevention protocols, have pushed hospitals toward adopting silver alloy and antibiotic-impregnated catheters. A funding boom has also emerged, with InfectionShield securing $45M in Series B funding to scale its IoT-enabled catheter tracking platform. Meanwhile, enterprise trends show a growing shift toward bundled payment models incentivizing infection reduction, accelerating adoption of preventive technologies. These developments signal a market prioritizing proactive, data-driven solutions to combat HAUTI.

Analyst Overview

The hospital acquired urinary tract infection market outlook remains attractive, driven by rising hospitalization rates, an aging population, and increasing prevalence of indwelling catheter use. Market growth is further supported by stringent regulatory frameworks promoting infection control and advancements in antimicrobial technologies. Competitive intensity is moderate, with established players dominating diagnostics and prophylactic treatments, while niche innovators focus on preventive devices and rapid detection tools. The long-term outlook is optimistic, buoyed by growing healthcare expenditure and a shift toward value-based care models prioritizing patient safety. The innovation landscape is dynamic, with R&D efforts centered on biofilm-resistant catheters, AI-driven infection monitoring systems, and novel antimicrobial agents to combat drug-resistant strains. Demand–supply balance shows tension, as rising demand for preventive solutions outpaces current production capacities, particularly in emerging markets. Key risk factors include regulatory compliance costs, antimicrobial resistance challenges, and reimbursement constraints in low-income regions. Strategic collaborations and investment in R&D will be critical for sustaining growth.

11 items

1. Executive Summary

2. hospital acquired urinary tract infection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global hospital acquired urinary tract infection Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global hospital acquired urinary tract infection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Disease Testing

6.1.2. Drug-resistance Testing

6.2. Global hospital acquired urinary tract infection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Microbial Testing Instruments

6.2.2. Reagents and Consumables

6.2.3. Infection Prevention and Surveillance Software

6.3. Global hospital acquired urinary tract infection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global hospital acquired urinary tract infection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global hospital acquired urinary tract infection Market by: Regions (Value)

8. Global hospital acquired urinary tract infection Market Competition by Key Manufacturers

8.1. Global hospital acquired urinary tract infection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global hospital acquired urinary tract infection: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Advanced Sterilization Products

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Becton, Dickinson and Company

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Steris Corporation

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Getinge Group

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Kimberly-Clark Corporation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Cantel Medical

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Biomerieux

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Belimed

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. 3M Company

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Sterigenics International

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Synergy Health

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global hospital acquired urinary tract infection Market

Figure 4: Global hospital acquired urinary tract infection Market: Drivers

Figure 5: Global hospital acquired urinary tract infection Market: Challenges

Figure 6: Global hospital acquired urinary tract infection Market: Trends

Figure 7: Global hospital acquired urinary tract infection Market: Opportunity

Figure 8: Global hospital acquired urinary tract infection Market: Restraint

Figure 9: Global hospital acquired urinary tract infection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global hospital acquired urinary tract infection Market Value (USD Million) By Region

Figure 15: Global hospital acquired urinary tract infection Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global hospital acquired urinary tract infection Market Value (USD Million) By Region

Figure 23: Global hospital acquired urinary tract infection Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global hospital acquired urinary tract infection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global hospital acquired urinary tract infection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global hospital acquired urinary tract infection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global hospital acquired urinary tract infection Market Value (USD Million) By Region

Table 10: Global hospital acquired urinary tract infection Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global hospital acquired urinary tract infection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global hospital acquired urinary tract infection Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global hospital acquired urinary tract infection Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Advanced Sterilization Products Basic Information And Sales Area

Table 31: Advanced Sterilization Products. Products Portfolio

Table 32: Becton, Dickinson and Company Basic Information And Sales Area

Table 33: Becton, Dickinson and Company. Products Portfolio

Table 34: Steris Corporation Basic Information And Sales Area

Table 35: Steris Corporation. Products Portfolio

Table 36: Getinge Group Basic Information And Sales Area

Table 37: Getinge Group. Products Portfolio

Table 38: Kimberly-Clark Corporation Basic Information And Sales Area

Table 39: Kimberly-Clark Corporation. Products Portfolio

Table 40: Cantel Medical Basic Information And Sales Area

Table 41: Cantel Medical. Products Portfolio

Table 42: Biomerieux Basic Information And Sales Area

Table 43: Biomerieux. Products Portfolio

Table 44: Belimed Basic Information And Sales Area

Table 45: Belimed. Products Portfolio

Table 46: 3M Company Basic Information And Sales Area

Table 47: 3M Company. Products Portfolio

Table 48: Sterigenics International Basic Information And Sales Area

Table 49: Sterigenics International. Products Portfolio

Table 50: Synergy Health Basic Information And Sales Area

Table 51: Synergy Health. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global hospital acquired urinary tract infection Market Value (USD Million) By Region

Table 57: Global hospital acquired urinary tract infection Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

hospital acquired urinary tract infection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	4.36 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Advanced Sterilization Products; Becton, Dickinson and Company; Steris Corporation; Getinge Group; Kimberly-Clark Corporation; Cantel Medical; Biomerieux; Belimed; 3M Company; Sterigenics International; Synergy Health
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

hospital acquired urinary tract infection Segmentation Breakdown7 items

Application

Disease Testing

Drug-resistance Testing

Types

Microbial Testing Instruments

Reagents and Consumables

Infection Prevention and Surveillance Software

Regional Insights

Loading chart…

Competitive Landscape

Advanced Sterilization Products: Premium pricing for sterilization solutions

Becton, Dickinson and Company: Innovation pipeline for antimicrobial catheters

Steris Corporation: Vertical integration in infection prevention systems

Kimberly-Clark Corporation: Regional expansion in emerging markets

Cantel Medical: OEM tie-ups for renal therapy devices

Biomerieux: Diagnostic partnerships to enhance UTI detection

Key hospital acquired urinary tract infection Companies11 items

Advanced Sterilization Products

Becton, Dickinson and Company

Steris Corporation

Getinge Group

Kimberly-Clark Corporation

Cantel Medical

Biomerieux

Belimed

3M Company

Sterigenics International

Synergy Health

Market Ecosystem

Raw material/component suppliers — Supply catheters, antiseptics, and antimicrobial agents for infection prevention and treatment

OEMs/Manufacturers — Produce medical devices and pharmaceuticals for UTI management

Technology providers — Develop antimicrobial coatings and diagnostic tools

System integrators — Implement infection control protocols and training programs

Distributors/Channel partners — Facilitate distribution of medical products to healthcare facilities

Regulators/Standards bodies — Establish guidelines for device approval and infection prevention compliance

End users/Healthcare facilities — Apply products and services to manage hospital-acquired UTIs

Recent Industry Insights

Analyst Overview

Table of Contents